PhaseBio Pharmaceuticals, Inc.

PHAS · NASDAQ
Analyze with AI
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Operating Activities
Net Income-$131-$98,565-$39,247-$23,846
Dep. & Amort.$1,793$508$174$105
Deferred Tax$0$0$0$0
Stock-Based Comp.$2,268$2,237$1,421$332
Change in WC$29,368-$4,262-$2,442$2,027
Other Non-Cash-$80,714$40,125$500$4,329
Operating Cash Flow-$47,416-$59,957-$39,594-$17,053
Investing Activities
PP&E Inv.-$2,679-$1,412-$960-$119
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow-$2,679-$1,412-$960-$119
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$60,354$2,942$46,277$42,974
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$63,773$15,466$53,528$64,797
Financing Cash Flow$63,773$15,466$53,528$64,797
Forex Effect$0$0$0$0
Net Chg. in Cash$13,678-$45,903$12,974$47,625
Supplemental Information
Beg. Cash$28,122$74,025$61,051$13,426
End Cash$41,800$28,122$74,025$61,051
Free Cash Flow-$50,095-$61,369-$40,554-$17,172
PhaseBio Pharmaceuticals, Inc. (PHAS) Financial Statements & Key Stats | AlphaPilot